SEMNL, headquartered in Beijing, is committed to the R&D, production and sales of bioactive peptide with biotechnology at the core. It is a high-tech enterprise recognized by the municipality of Beijing and the state, and has set up three major marketing and service centers in Beijing, Shanghai and Guangzhou. SEMNL lands the Bioactive Peptide Health Research Institute in cooperation with the Institute of Process Engineering, Chinese Academy of Sciences (CAS), and the bioactive-peptide production base in Huaibei, Anhui Province. So far, its product portfolio includes collagen peptide, SEMFLEX-II® undenatured type II collagen, type III collagen peptide, PGXR® oligopeptide, SEMPEP-II®hydrolyzed type II collagen,oyster extract, elastin peptide, collagen tripeptide and so on. 

SEMNL has applied for nearly 100 patents, and is granted 50 of them; presided over a number of provincial and ministerial-level research projects and the formulation of a number of group standards; published more than 30 research papers, including several on SCI and EI. In particular, based on the joint evaluation of bioactive peptide efficacy we conducted with Peking University School of Public Health, the book On Fish Collagen Peptides Nutrition was prepared. SEMNL won the first prize of Science and Technology from China General chamber of commerce in 2023.

SEMNL’s production base has highly automated production lines for bioactive peptides(Hydrolyzed fish collagen, Hydrolyzed bovine collagen and so on) with annual output of 6000 tons and 100 tons of undenatured type II collagen, which has obtained ISO 9001, HACCP, MSC, HALAL and BRC certifications and registered in FDA and EFDA. SEMNL is managed in strict accordance with the quality control system, ensuring product safety and quality consistency.